Einzeltreffer — DigiBib

Essential thrombocythemia is a chronic myeloproliferative neoplasm characterized by sustained thrombocytosis, bone marrow megakaryocytic hyperplasia and an increased risk of thrombosis and hemorrhage. The goal of treatment is to prevent the development of vascular complications without increasing the risk of transformation. Patients aged>60 years or a history of thrombosis have a high risk of thrombosis while those with a platelet count>1,500 x 10(9)/l have a higher risk of hemorrhage. Patients with low-risk essential thrombocythemia can be managed appropriately with low-dose of acetylsalicylic acid or even observation only, while patients with a high-risk disease are candidates to receive cytoreductive treatment, hydroxyurea being the first choice therapy. Anagrelide is the most suitable option for patients with resistance or intolerance to hydroxyurea. All patients must be submitted to a rigorous control of cardiovascular risk factors.

Titel:	[Treatment of essential thrombocythemia].
Autor/in / Beteiligte Person:	Alvarez-Larrán, A ; Cervantes, F ; Besses, C
Zeitschrift:	Medicina clinica, Jg. 141 (2013-09-21), Heft 6, S. 260-4
Veröffentlichung:	<2009- > : Madrid : Elsevier España ; <i>Original Publication</i>: Barcelona : Ediciones Doyma, S.A., 2013
Medientyp:	academicJournal
ISSN:	1578-8989 (electronic)
DOI:	10.1016/j.medcli.2013.01.016
Schlagwort:	Adult Age Factors Aged Anticoagulants adverse effects Anticoagulants therapeutic use Aspirin adverse effects Aspirin therapeutic use Cell Transformation, Neoplastic genetics Disease Progression Female Hemorrhage chemically induced Hemorrhage etiology Hemorrhage prevention & control Heparin, Low-Molecular-Weight adverse effects Heparin, Low-Molecular-Weight therapeutic use Humans Hydroxyurea therapeutic use Intraoperative Complications prevention & control Janus Kinase 2 genetics Leukemia, Myeloid, Acute etiology Leukemia, Myeloid, Acute prevention & control Life Expectancy Male Middle Aged Mutation, Missense Platelet Aggregation Inhibitors adverse effects Platelet Aggregation Inhibitors therapeutic use Point Mutation Pregnancy Pregnancy Complications, Hematologic Primary Myelofibrosis etiology Quinazolines therapeutic use Risk Factors Thrombocythemia, Essential complications Thrombocythemia, Essential genetics Thrombophilia drug therapy Thrombophilia etiology Thrombocythemia, Essential drug therapy
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: Spanish; Castilian Transliterated Title: Tratamiento de la trombocitemia esencial. Publication Type: Journal Article; Review Language: Spanish; Castilian [Med Clin (Barc)] 2013 Sep 21; Vol. 141 (6), pp. 260-4. <i>Date of Electronic Publication: </i>2013 Mar 13. MeSH Terms: Thrombocythemia, Essential / *drug therapy ; Adult ; Age Factors ; Aged ; Anticoagulants / adverse effects ; Anticoagulants / therapeutic use ; Aspirin / adverse effects ; Aspirin / therapeutic use ; Cell Transformation, Neoplastic / genetics ; Disease Progression ; Female ; Hemorrhage / chemically induced ; Hemorrhage / etiology ; Hemorrhage / prevention & control ; Heparin, Low-Molecular-Weight / adverse effects ; Heparin, Low-Molecular-Weight / therapeutic use ; Humans ; Hydroxyurea / therapeutic use ; Intraoperative Complications / prevention & control ; Janus Kinase 2 / genetics ; Leukemia, Myeloid, Acute / etiology ; Leukemia, Myeloid, Acute / prevention & control ; Life Expectancy ; Male ; Middle Aged ; Mutation, Missense ; Platelet Aggregation Inhibitors / adverse effects ; Platelet Aggregation Inhibitors / therapeutic use ; Point Mutation ; Pregnancy ; Pregnancy Complications, Hematologic ; Primary Myelofibrosis / etiology ; Quinazolines / therapeutic use ; Risk Factors ; Thrombocythemia, Essential / complications ; Thrombocythemia, Essential / genetics ; Thrombophilia / drug therapy ; Thrombophilia / etiology Contributed Indexing: Keywords: Essential thrombocythemia; Factores de riesgo; Risk factors; Tratamiento; Treatment; Trombocitemia esencial Substance Nomenclature: 0 (Anticoagulants) ; 0 (Heparin, Low-Molecular-Weight) ; 0 (Platelet Aggregation Inhibitors) ; 0 (Quinazolines) ; EC 2.7.10.2 (JAK2 protein, human) ; EC 2.7.10.2 (Janus Kinase 2) ; K9X45X0051 (anagrelide) ; R16CO5Y76E (Aspirin) ; X6Q56QN5QC (Hydroxyurea) Entry Date(s): Date Created: 20130316 Date Completed: 20140414 Latest Revision: 20161125 Update Code: 20240513

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

[Treatment of essential thrombocythemia].